Illumina collaborates with 54gene in the creation of a world-class genomics facility in Nigeria
Partnership will expand 54gene’s sequencing-based research and molecular diagnostics capabilities with a focus on improving health outcomes through precision medicine
03 September, 2020, Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration with 54gene, a health technology company whose mission is to advance precision medicine capabilities in Africa through research, advanced molecular diagnostics and clinical programs. The partnership will support the establishment of a new genetics facility in Lagos, Nigeria, equipped with a suite of Illumina's cutting-edge sequencing and high-density microarray technology platforms, which will generate genetic information for health research and drug development.
Africa contains more genetic diversity than any other continent because the Afri...